Sildenafil Actavis

sildenafil

Overview
Authorisation details
Product information
Assessment history

Authorised

This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).

: Sildenafil Actavis is a medicine that contains the active substance sildenafil. It is available as tablets (25, 50 and 100 mg).
Sildenafil Actavis is a ‘generic medicine’. This means that Sildenafil Actavis is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Viagra.

: Sildenafil Actavis is used to treat adult men with erectile dysfunction (sometimes called impotence), when they cannot get or keep a hard penis (erection) sufficient for satisfactory sexual activity. For Sildenafil Actavis to be effective, sexual stimulation is required.
The medicine can only be obtained with a prescription.

: The recommended dose of Sildenafil Actavis is 50 mg taken as needed about one hour before sexual activity. If Sildenafil Actavis is taken with food, the onset of activity may be delayed compared with taking Sildenafil Actavis without food. The dose may be increased to a maximum of 100 mg or decreased to 25 mg depending on the effectiveness and side effects. Patients with liver problems or severe kidney problems should start treatment with the 25-mg dose. The maximum recommended dosing frequency is one tablet per day.

: The active ingredient in Sildenafil Actavis, sildenafil, belongs to a group of medicines called phosphodiesterase-type-5 (PDE5) inhibitors. It works by blocking the phosphodiesterase enzyme, which normally breaks down a substance known as cyclic guanosine monophosphate (cGMP). During normal sexual stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the corpora cavernosa) to relax. This allows blood to flow into the corpora, producing the erection. By blocking the breakdown of cGMP, Sildenafil Actavis restores erectile function. Sexual stimulation is still needed to produce an erection.

: Because Sildenafil Actavis is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Viagra. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

: Because Sildenafil Actavis is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

: The CHMP concluded that, in accordance with EU requirements, Sildenafil Actavis has been shown to have comparable quality and to be bioequivalent to Viagra. Therefore, the CHMP’s view was that, as for Viagra, the benefit outweighs the identified risk. The Committee recommended that Sildenafil Actavis be given marketing authorisation.

: The European Commission granted a marketing authorisation valid throughout the European Union for Sildenafil Actavis on 10 December 2009.
For more information about treatment with Sildenafil Actavis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

List item

Sildenafil Actavis : EPAR - Summary for the public (PDF/90.26 KB)

First published: 21/12/2009
Last updated: 11/05/2015
- Bulgarian
  (PDF/142.22 KB)
- Croatian
  (PDF/101.74 KB)
- Czech
  (PDF/116.17 KB)
- Danish
  (PDF/90.06 KB)
- Dutch
  (PDF/90.72 KB)
- Estonian
  (PDF/89.49 KB)
- Finnish
  (PDF/111.94 KB)
- French
  (PDF/91.88 KB)
- German
  (PDF/91.47 KB)
- Greek
  (PDF/124.5 KB)
- Hungarian
  (PDF/112.57 KB)
- Italian
  (PDF/89.98 KB)
- Latvian
  (PDF/112.57 KB)
- Lithuanian
  (PDF/113.39 KB)
- Maltese
  (PDF/116.86 KB)
- Polish
  (PDF/116.35 KB)
- Portuguese
  (PDF/90.71 KB)
- Romanian
  (PDF/111.68 KB)
- Slovak
  (PDF/114.97 KB)
- Slovenian
  (PDF/105.97 KB)
- Spanish
  (PDF/92.49 KB)
- Swedish
  (PDF/91.1 KB)

More detail is available in the summary of product characteristics

This EPAR was last updated on 04/12/2018

Authorisation details

Product details
Name	Sildenafil Actavis
Agency product number	EMEA/H/C/001090
Active substance	sildenafil
International non-proprietary name (INN) or common name	sildenafil
Therapeutic area (MeSH)	Erectile Dysfunction
Anatomical therapeutic chemical (ATC) code	G04BE03
Generic	This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder	Actavis Group PTC ehf
Revision	12
Date of issue of marketing authorisation valid throughout the European Union	10/12/2009
Contact address	Reykjavíkurvegur 76 - 78 IS-220 Hafnarfjörður Iceland

Product information

14/11/2018 Sildenafil Actavis - EMEA/H/C/001090 - N/0019

List item

Sildenafil Actavis : EPAR - Product Information (PDF/194.04 KB)

First published: 07/05/2018
Last updated: 04/12/2018
- Bulgarian
  (PDF/369.81 KB)
- Croatian
  (PDF/337.75 KB)
- Czech
  (PDF/336.34 KB)
- Danish
  (PDF/283.28 KB)
- Dutch
  (PDF/282.39 KB)
- Estonian
  (PDF/313.74 KB)
- Finnish
  (PDF/285.95 KB)
- French
  (PDF/298.47 KB)
- German
  (PDF/296.28 KB)
- Greek
  (PDF/399.33 KB)
- Hungarian
  (PDF/349.68 KB)
- Icelandic
  (PDF/283.23 KB)
- Italian
  (PDF/290.27 KB)
- Latvian
  (PDF/350.87 KB)
- Lithuanian
  (PDF/346.32 KB)
- Maltese
  (PDF/372.42 KB)
- Norwegian
  (PDF/283.98 KB)
- Polish
  (PDF/372.23 KB)
- Portuguese
  (PDF/288.39 KB)
- Romanian
  (PDF/358.29 KB)
- Slovak
  (PDF/342.03 KB)
- Slovenian
  (PDF/330.01 KB)
- Spanish
  (PDF/292.3 KB)
- Swedish
  (PDF/283.79 KB)

Annex I - Summary of product characteristics
Annex IIA - Manufacturing-authorisation holder responsible for batch release
Annex IIB - Conditions of the marketing authorisation
Annex IIIA - Labelling
Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

List item

Sildenafil Actavis : EPAR - All Authorised presentations (PDF/8.74 KB)

First published: 21/12/2009
Last updated: 08/07/2016
- Bulgarian
  (PDF/32.14 KB)
- Croatian
  (PDF/14.61 KB)
- Czech
  (PDF/14.47 KB)
- Danish
  (PDF/8.55 KB)
- Dutch
  (PDF/8.31 KB)
- Estonian
  (PDF/11.28 KB)
- Finnish
  (PDF/12.11 KB)
- French
  (PDF/12.14 KB)
- German
  (PDF/8.53 KB)
- Greek
  (PDF/30.42 KB)
- Hungarian
  (PDF/22.46 KB)
- Icelandic
  (PDF/11.61 KB)
- Italian
  (PDF/10.8 KB)
- Latvian
  (PDF/23.19 KB)
- Lithuanian
  (PDF/24.08 KB)
- Maltese
  (PDF/22.46 KB)
- Norwegian
  (PDF/9.12 KB)
- Polish
  (PDF/14.21 KB)
- Portuguese
  (PDF/11.27 KB)
- Romanian
  (PDF/22.21 KB)
- Slovak
  (PDF/14.84 KB)
- Slovenian
  (PDF/11.44 KB)
- Spanish
  (PDF/11.63 KB)
- Swedish
  (PDF/8.77 KB)

Pharmacotherapeutic group

Urologicals

Therapeutic indication

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

In order for Sildenafil Actavis to be effective, sexual stimulation is required.

Assessment history

Changes since initial authorisation of medicine

List item

Sildenafil Actavis : EPAR - Procedural steps taken and scientific information after authorisation (PDF/94.49 KB)

First published: 13/04/2011
Last updated: 04/12/2018

Sildenafil Actavis

Table of contents

Overview